KR20250171410A - 합성 종양용해성 lnp-레플리콘 rna 및 암 면역요법을 위한 용도 - Google Patents

합성 종양용해성 lnp-레플리콘 rna 및 암 면역요법을 위한 용도

Info

Publication number
KR20250171410A
KR20250171410A KR1020257038746A KR20257038746A KR20250171410A KR 20250171410 A KR20250171410 A KR 20250171410A KR 1020257038746 A KR1020257038746 A KR 1020257038746A KR 20257038746 A KR20257038746 A KR 20257038746A KR 20250171410 A KR20250171410 A KR 20250171410A
Authority
KR
South Korea
Prior art keywords
replicon rna
cells
mtrep
rna
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257038746A
Other languages
English (en)
Korean (ko)
Inventor
다렐 제이. 어바인
칼 대인 윗트럽
론 와이스
잉중 리
누르 무민
이조우 동
Original Assignee
메사추세츠 인스티튜트 오브 테크놀로지
오하이오 스테이트 이노베이션 파운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메사추세츠 인스티튜트 오브 테크놀로지, 오하이오 스테이트 이노베이션 파운데이션 filed Critical 메사추세츠 인스티튜트 오브 테크놀로지
Publication of KR20250171410A publication Critical patent/KR20250171410A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020257038746A 2019-03-08 2020-01-10 합성 종양용해성 lnp-레플리콘 rna 및 암 면역요법을 위한 용도 Pending KR20250171410A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962815611P 2019-03-08 2019-03-08
US62/815,611 2019-03-08
PCT/US2020/013069 WO2020185293A1 (en) 2019-03-08 2020-01-10 Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
KR1020217032460A KR102889984B1 (ko) 2019-03-08 2020-01-10 합성 종양용해성 lnp-레플리콘 rna 및 암 면역요법을 위한 용도

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217032460A Division KR102889984B1 (ko) 2019-03-08 2020-01-10 합성 종양용해성 lnp-레플리콘 rna 및 암 면역요법을 위한 용도

Publications (1)

Publication Number Publication Date
KR20250171410A true KR20250171410A (ko) 2025-12-08

Family

ID=69526302

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257038746A Pending KR20250171410A (ko) 2019-03-08 2020-01-10 합성 종양용해성 lnp-레플리콘 rna 및 암 면역요법을 위한 용도
KR1020217032460A Active KR102889984B1 (ko) 2019-03-08 2020-01-10 합성 종양용해성 lnp-레플리콘 rna 및 암 면역요법을 위한 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217032460A Active KR102889984B1 (ko) 2019-03-08 2020-01-10 합성 종양용해성 lnp-레플리콘 rna 및 암 면역요법을 위한 용도

Country Status (17)

Country Link
US (3) US11717548B2 (https=)
EP (2) EP3934673B1 (https=)
JP (2) JP7561134B2 (https=)
KR (2) KR20250171410A (https=)
CN (1) CN113966221B (https=)
AU (1) AU2020233788A1 (https=)
BR (1) BR112021017637A8 (https=)
CA (1) CA3132714A1 (https=)
CO (1) CO2021013417A2 (https=)
DK (1) DK3934673T3 (https=)
FI (1) FI3934673T3 (https=)
IL (1) IL285963A (https=)
MX (1) MX2021010808A (https=)
MY (1) MY207334A (https=)
PH (1) PH12021552145A1 (https=)
SG (1) SG11202109514VA (https=)
WO (1) WO2020185293A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113710229B (zh) 2019-02-25 2026-01-06 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
DK3934673T3 (da) * 2019-03-08 2026-04-07 Massachusetts Inst Technology Syntetisk onkolytisk lnp-replikon-rna og anvendelser til cancerimmunterapi
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
CN113509542A (zh) * 2021-04-20 2021-10-19 嘉晨西海(杭州)生物技术有限公司 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法
CZ310443B6 (cs) * 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
EP4514328A1 (en) 2022-04-26 2025-03-05 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
CN115227674B (zh) * 2022-08-05 2023-07-04 武汉滨会生物科技股份有限公司 包封的溶瘤病毒遗传物质及其应用
EP4648781A1 (en) * 2023-01-12 2025-11-19 Bavarian Nordic A/S Recombinant modified sarna (vrp) for cancer vaccine
CN121311221A (zh) * 2023-04-07 2026-01-09 旗舰实验室114股份有限公司 用于治疗性脂质纳米颗粒 (lnp)递送的脂质和脂质样化合物
CN118147171B (zh) * 2024-03-08 2024-12-06 上海复诺健生物科技有限公司 具有增强的外源基因表达水平的自扩增mRNA核酸序列
AU2024299882A1 (en) 2023-07-25 2026-01-08 Strand Therapeutics Inc. Polynucleotides comprising a micro rna detargeting sensor and uses thereof
WO2025087372A1 (zh) * 2023-10-27 2025-05-01 上海元宋生物技术有限公司 溶瘤病毒及其用途
CN119479778B (zh) * 2024-10-16 2025-04-25 北京悦康科创医药科技股份有限公司 一种lnp转染效率预测模型构建方法及装置
CN121081290B (zh) * 2025-11-12 2026-03-10 佑嘉(杭州)生物医药科技有限公司 一种毛囊靶向递送系统及生发防脱化妆品

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US20110300205A1 (en) * 2009-07-06 2011-12-08 Novartis Ag Self replicating rna molecules and uses thereof
RS63817B1 (sr) 2010-07-06 2023-01-31 Glaxosmithkline Biologicals Sa Čestice za isporuku slične virionu za molekule samoreplicirajuće rnk
US11058762B2 (en) * 2011-07-06 2021-07-13 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
WO2014089061A1 (en) * 2012-12-03 2014-06-12 Yasuko Rikihisa Ehrlichial invasin for immunization, diagnosis, and cell delivery
US10125092B2 (en) * 2014-09-05 2018-11-13 Novartis Ag Lipids and lipid compositions for the delivery of active agents
JP7523203B2 (ja) * 2014-10-31 2024-07-26 マサチューセッツ インスティテュート オブ テクノロジー 生体分子の免疫細胞への送達
DK3297637T3 (da) 2015-05-21 2021-08-02 Ohio State Innovation Foundation Benzen-1,3,5-tricarboxamidderivater og anvendelser deraf
DK3934673T3 (da) * 2019-03-08 2026-04-07 Massachusetts Inst Technology Syntetisk onkolytisk lnp-replikon-rna og anvendelser til cancerimmunterapi
JP2023535225A (ja) * 2020-07-24 2023-08-16 ストランド セラピューティクス インコーポレイテッド 改変ヌクレオチドを含む脂質ナノ粒子
US20240140960A1 (en) * 2021-02-12 2024-05-02 Ohio State Innovation Foundation Sugar derived lipid nanomaterials and uses thereof
EP4367253A4 (en) * 2021-07-09 2025-06-04 Replicate Bioscience, Inc. Modified eastern equine encephalitis viruses, self-replicating rna constructs, and uses thereof
CN117180454A (zh) * 2022-05-16 2023-12-08 上海行深生物科技有限公司 含有自复制rna分子和脂质纳米颗粒递送载体的组合物及其制备方法

Also Published As

Publication number Publication date
WO2020185293A1 (en) 2020-09-17
KR20220006041A (ko) 2022-01-14
EP3934673A1 (en) 2022-01-12
JP2025011109A (ja) 2025-01-23
US20240024394A1 (en) 2024-01-25
BR112021017637A2 (https=) 2021-11-09
KR102889984B1 (ko) 2025-11-25
US20260061013A1 (en) 2026-03-05
CA3132714A1 (en) 2020-09-17
CN113966221A (zh) 2022-01-21
EP3934673B1 (en) 2026-01-07
SG11202109514VA (en) 2021-09-29
EP4729621A2 (en) 2026-04-22
DK3934673T3 (da) 2026-04-07
JP2022524391A (ja) 2022-05-02
CN113966221B (zh) 2026-03-31
FI3934673T3 (fi) 2026-03-31
US12383589B2 (en) 2025-08-12
CO2021013417A2 (es) 2022-01-17
US11717548B2 (en) 2023-08-08
JP7561134B2 (ja) 2024-10-03
PH12021552145A1 (en) 2022-08-31
AU2020233788A1 (en) 2021-10-07
IL285963A (en) 2021-10-31
BR112021017637A8 (pt) 2022-08-16
US20200281994A1 (en) 2020-09-10
MX2021010808A (es) 2021-12-15
MY207334A (en) 2025-02-19

Similar Documents

Publication Publication Date Title
KR102889984B1 (ko) 합성 종양용해성 lnp-레플리콘 rna 및 암 면역요법을 위한 용도
KR102794870B1 (ko) 핵산을 와우 및 전정 세포에 전달하기 위한 물질 및 방법
CN110856724B (zh) 包含核酸及car修饰的免疫细胞的治疗剂及其应用
AU2016214301B2 (en) Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
AU2023214288A1 (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
KR101255419B1 (ko) 인플루엔자 바이러스의 다중 아형에 대한 신규 백신
CN107746845B (zh) 特异性靶向LAG-3基因的sgRNA和特异性敲除LAG-3基因的方法
KR20210154176A (ko) 표적화된 생체내 후성유전학적 억제에 의한 장기지속성 진통
KR20210043574A (ko) 푸소좀 조성물 및 이의 용도
JP7644007B2 (ja) 第ｉｘ因子を発現するレンチウイルスベクターの使用
AU2018367546B2 (en) Methods and compositions for non-myeloablative bone marrow reconstitution
KR20240022575A (ko) 아머링된 키메라 수용체 및 이의 사용 방법
RU2771383C2 (ru) Контролируемая пищевым рационом экспрессия нуклеиновой кислоты, кодирующей нуклеазу cas9, и ее применения
CN114008209A (zh) Aav介导的枫糖尿症(msud)基因疗法
KR20210102247A (ko) Crispr 수퍼-리프레서에 의한 생체내 합성 면역조절
JP2023065516A (ja) 結節性硬化症の遺伝子治療
CN112725344B (zh) 密码子优化的smn1基因、腺相关病毒表达质粒及基因药物
CN108379597B (zh) 一种基因载体及其用于治疗视网膜神经节细胞变性的基因治疗药物
CN107760680B (zh) 特异性靶向TIM-3基因的sgRNA和特异性敲除TIM-3基因的方法
KR102679920B1 (ko) 모노머형 스트렙타비딘을 발현하는 균주 및 비오틴화된 화합물을 포함하는 암 세포 표적용 조성물
KR20060002745A (ko) 치료적 생성물의 전달을 위한 증식성 줄기세포 및전구세포에서의 후보 분자의 지속적 발현
RU2809724C2 (ru) Синтетический онколитический lnp-репликон рнк и применения для иммунотерапии злокачественных опухолей
CN117795086A (zh) 用于枫糖尿症(msud)中bcaa调节的基因疗法
CN108159434B (zh) 一种基因载体及其用于治疗青光眼的基因治疗药物
CN115298307A (zh) 核酸调节元件的新组合及其方法和用途

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)